Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.
Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.
Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.
Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.
The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.
CS1/CRACC/SLAMF7, His & Avi, Human
CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses.
| Z03649 | |
|
|
|
| ¥36,250.00 | |
|
|
|
|
|
|
| Ask us a question | |
